Skip to main content

Table 2 Safety measures at visit 1 and visit 2 in patients receiving chicory

From: Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee

Variable Measured

Cohort 1

Cohort 2

Cohort 3

 

(N = 4)*

(N = 4)

(N = 13)

 

Visit 1

Visit 2

P**

Visit 1

Visit 2

P

Visit 1

Visit 2

P

BP Syst (mm Hg)

136 ± 9.3

128 ± 9.9

0.40

144 ± 7.8

141 ± 3.5

0.80

138 ± 5.7

142 ± 5.4

0.39

BP Diast (mm Hg)

83 ± 6.6

82 ± 5.5

0.86

78 ± 10.1

88 ± 3.7

0.46

96 ± 2.3

88 ± 3.4

0.04

HR (BPM)

69 ± 4.2

77 ± 4.6

0.01

74 ± 9.2

76 ± 9.4

0.74

72 ± 3.7

71 ± 4.3

0.65

WBC† (cell/mm3)

6.1 ± 0.6

6.1 ± 0.3

0.48

6.6 ± 1.2

5.9 ± 0.9

0.20

6.9 ± 0.5

6.6 ± 0.2

0.34

Hgb (g/dL)

12.8 ± 0.8

12.6 ± 0.7

0.23

14.4 ± 0.9

14.5 ± 0.8

0.25

14.6 ± 0.2

14.1 ± 0.3

0.02

Creatinine (mg/dL)

0.78 ± 0.08

0.78 ± 0.07

1

0.68 ± 0.11

0.70 ± 0.11

0.39

0.83 ± 0.04

0.84 ± 0.04

0.67

AST (U/L)

17.3 ± 1.8

17.8 ± 0.5

0.81

24.0 ± 3.5

25.0 ± 5.0

0.57

21.9 ± 2.4

22.3 ± 2.4

0.86

  1. * Patients included in this analysis were those receiving chicory who had lab values available at both baseline and final visits. Values represent mean and S.E.M.
  2. ** P values calculated using paired t-test, V1 vs V2.
  3. †Normal range: WBC 4.1-11.1 × 10/μL.